Tezepelumab for severe asthma: final report
- Collection:
- Health Policy and Services Research
- Author(s):
- Rind, David M., author McQueen, Brett, author Herron-Smith, Serina, author Herce-Hagiwara, Belén, author Gutierrez, Éric, author Fluetsch, Noemi, author Pearson, Steven D., author
- Contributor(s):
- Institute for Clinical and Economic Review, issuing body.
- Publication:
- [Boston, Massachusetts] : Institute for Clinical and Economic Review, December 16, 2021
- Language(s):
- English
- Format:
- Text
- Subject(s):
- Antibodies, Monoclonal, Humanized Asthma -- drug therapy United States
- Genre(s):
- Technical Report
- Abstract:
- The Centers for Disease Control and Prevention (CDC) estimates that 25 million Americans, including 5 million children, have asthma. Asthma leads to approximately 1.6 million emergency room visits, 180,000 hospitalizations, and 3,500 deaths each year in the US. The societal costs are estimated to be $82 billion, including $50 billion in direct medical costs, $29 billion from asthmarelated mortality, and $3 billion from missed work and school.2 In the US, asthma is more than twice as common among Black children as among White children (13.5% and 6.4%, respectively), and remains somewhat more common among Black adults. Patients with severe asthma represent fewer than 5-10% of all individuals with asthma. Asthma has been divided into different phenotypes with some overlap. About half of individuals with mild-to-moderate asthma exhibit the type 2 phenotype, and the proportion is believed to be larger in severe asthma. Allergic asthma and eosinophilic asthma are generally forms of type 2 asthma. None of the five biologic therapies that ICER reviewed in 2018 appeared to be effective for patients who had neither allergic asthma nor eosinophilia. Tezepelumab is a new monoclonal antibody that targets thymic stromal lymphopoietin (TSLP). It is administered by subcutaneous injection every four weeks. In this report, we review the clinical effectiveness of tezepelumab for severe asthma and also compare it with agents indicated for certain subpopulations: 1) omalizumab for patients with allergic asthma; and 2) dupilumab for patients with eosinophilic asthma. We also compare the efficacy of tezepelumab and dupilumab in patients dependent on chronic oral corticosteroids. Patients, patient groups, and clinicians have emphasized the need for treatments that allow patients to return to their usual activities of daily living. Symptom relief, asthma control, and quality of life matter much more to patients than a reduction in asthma exacerbations.
- Copyright:
- Reproduced with permission of the copyright holder. Further use of the material is subject to CC BY license. (More information)
- Extent:
- 1 online resource (1 PDF file (various pagings))
- Illustrations:
- Illustrations
- NLM Unique ID:
- 9918401086406676 (See catalog record)
- Permanent Link:
- http://resource.nlm.nih.gov/9918401086406676